NKTR Nektar Therapeutics

Price (delayed)

$16.5

Market cap

$3.03B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.63

Enterprise value

$3.03B

Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. ...

Highlights
The debt has decreased by 5% YoY
The gross profit has declined by 42% year-on-year and by 21% since the previous quarter
The revenue has contracted by 35% YoY and by 16% from the previous quarter

Key stats

What are the main financial stats of NKTR
Market
Shares outstanding
183.8M
Market cap
$3.03B
Enterprise value
$3.03B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.32
Price to sales (P/S)
28.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
28.72
Earnings
Revenue
$105.47M
EBIT
-$473.68M
EBITDA
-$460.1M
Free cash flow
-$321.12M
Per share
EPS
-$2.63
Free cash flow per share
-$1.76
Book value per share
$4.96
Revenue per share
$0.58
TBVPS
$7.09
Balance sheet
Total assets
$1.37B
Total liabilities
$466.38M
Debt
$148.43M
Equity
$904.98M
Working capital
$925.13M
Liquidity
Debt to equity
0.16
Current ratio
8.06
Quick ratio
7.85
Net debt/EBITDA
0.01
Margins
EBITDA margin
-436.2%
Gross margin
77.9%
Net margin
-449.7%
Operating margin
-410.9%
Efficiency
Return on assets
-32.3%
Return on equity
-45.7%
Return on invested capital
-37%
Return on capital employed
-38.2%
Return on sales
-449.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NKTR stock price

How has the Nektar Therapeutics stock price performed over time
Intraday
0.92%
1 week
1.04%
1 month
-10.86%
1 year
-5.93%
YTD
-2.94%
QTD
-8.13%

Financial performance

How have Nektar Therapeutics's revenue and profit performed over time
Revenue
$105.47M
Gross profit
$82.16M
Operating income
-$433.37M
Net income
-$474.28M
Gross margin
77.9%
Net margin
-449.7%
The net margin has shrunk by 70% YoY and by 32% QoQ
The operating margin has plunged by 59% YoY and by 29% from the previous quarter
The gross profit has declined by 42% year-on-year and by 21% since the previous quarter
The revenue has contracted by 35% YoY and by 16% from the previous quarter

Growth

What is Nektar Therapeutics's growth rate over time

Valuation

What is Nektar Therapeutics stock price valuation
P/E
N/A
P/B
3.32
P/S
28.58
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
28.72
Nektar Therapeutics's EPS has decreased by 10% QoQ and by 8% YoY
The P/B is 96% below the 5-year quarterly average of 78.3 but 6% above the last 4 quarters average of 3.1
Nektar Therapeutics's equity has decreased by 28% YoY and by 9% QoQ
The revenue has contracted by 35% YoY and by 16% from the previous quarter
The stock's P/S is 22% more than its 5-year quarterly average of 23.2 and 18% more than its last 4 quarters average of 24.1

Efficiency

How efficient is Nektar Therapeutics business performance
Nektar Therapeutics's return on sales has shrunk by 78% YoY and by 32% QoQ
The return on invested capital has dropped by 62% year-on-year and by 18% since the previous quarter
Nektar Therapeutics's ROE has decreased by 45% YoY and by 20% from the previous quarter
NKTR's ROA is down by 42% YoY and by 15% from the previous quarter

Dividends

What is NKTR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NKTR.

Financial health

How did Nektar Therapeutics financials performed over time
Nektar Therapeutics's total assets is 194% more than its total liabilities
The total liabilities has grown by 38% YoY
Nektar Therapeutics's total assets has decreased by 14% YoY and by 6% from the previous quarter
The debt is 84% lower than the equity
The debt to equity rose by 33% YoY and by 7% QoQ
Nektar Therapeutics's equity has decreased by 28% YoY and by 9% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.